Xiamen Humanity Hospital

CancerFax acts as your single Mandarin-speaking coordinator for the entire Xiamen Humanity Hospital journey. You begin by sharing your medical records, including pathology and biopsy findings, recent CT, PET-CT and MRI imaging (particularly important for BNCT treatment planning), prior chemotherapy, radiotherapy, targeted therapy and immunotherapy treatment summaries through our secure intake. Our clinical team reviews your case and identifies whether Xiamen Humanity Hospital is genuinely the right fit, particularly for patients with advanced refractory head and neck cancer, recurrent high-grade glioma, advanced melanoma or other refractory tumours where BNCT may offer a clinically meaningful option. We then submit your case to the hospital's BNCT Center, Oncology Center or appropriate sub-specialty department.

Once a clinical plan is confirmed, CancerFax prepares your full pre-travel pack: the hospital's official cost estimate translated into English (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited Chinese-English translation of your home-country reports, accommodation guidance in Xiamen, and travel logistics via Xiamen Gaoqi International Airport or via Hong Kong, Guangzhou or Shenzhen. We remain your single point of contact through admission, BNCT treatment cycles, discharge and post-treatment imaging follow-up. Where useful, we will openly compare Xiamen Humanity Hospital alongside alternative Chinese cancer centres (such as Lu Daopei Hospital for CAR-T, IHBDH Tianjin for haematology, or CAMS Cancer Hospital for solid tumour national-flagship care) and international BNCT pathways. There is no fee to the family for any of this coordination.

Boron Neutron Capture Therapy (BNCT) is a binary targeted radiotherapy technique that combines two components: a boron-containing drug (typically boronophenylalanine, or BPA) that is preferentially taken up by tumour cells, and an epithermal neutron beam that irradiates the tumour. When the neutron beam interacts with the boron atoms inside tumour cells, it generates high-energy alpha particles and lithium nuclei that travel only a very short distance, destroying the tumour cell while largely sparing surrounding normal tissue. BNCT is particularly relevant for cancers that have failed conventional treatment, that recur in previously irradiated areas where additional conventional radiotherapy is not possible, or that infiltrate normal tissue diffusely. At Xiamen Humanity Hospital, the active Investigator Initiated Trial since October 2022 enrolled patients with advanced refractory head and neck cancer, recurrent high-grade glioma (the most aggressive brain tumours) and melanoma where traditional cancer therapies had been exhausted. CancerFax assesses BNCT eligibility from your records before any travel commitment, since BNCT requires specific imaging, biomarker and prior treatment criteria. Worldwide BNCT capacity remains very limited, with the technology actively used at clinical scale only in Japan and now China.

This is an important distinction that CancerFax wants to be clear about. According to the hospital's architectural profile, Xiamen Humanity Hospital was constructed in compliance with Joint Commission International (JCI) hospital design standards (alongside the Chinese Erxing green building standard) when it opened in September 2018. This means the building itself was designed and built to JCI hospital infrastructure expectations. However, being built to JCI standard is different from holding active JCI accreditation, which is a separate audit-based certification of operational hospital quality. The hospital's specific current formal JCI accreditation status should be confirmed with the International Patient Centre before any travel commitment. The hospital is, however, formally accredited as a Phase I through IV drug clinical trial institution, and is also accredited for clinical trials of medical devices and in vitro diagnostic (IVD) products. CancerFax provides full transparency on this distinction and will update you on accreditation status as confirmed.

Yes, and this is particularly important for BNCT because eligibility depends on specific imaging, biomarker, prior treatment and tumour location criteria that can largely be assessed remotely. The standard process involves submitting your scans (especially recent MRI and PET-CT), pathology reports, prior radiotherapy treatment plans (since BNCT is often considered for patients who have had prior conventional radiotherapy), and current treatment summaries through CancerFax. We coordinate accredited Chinese-English translation, submit the records to the BNCT Center, follow up on your behalf and help you understand the resulting opinion. Where BNCT is not clinically appropriate but other Chinese cancer treatment pathways may be, we will discuss alternatives including Lu Daopei Hospital (CAR T-cell therapy for haematological cases), IHBDH Tianjin (haematology national centre), Cancer Hospital of the Chinese Academy of Medical Sciences (solid tumour national flagship), or international alternatives. A remote BNCT opinion is the most efficient first step before committing to international travel.

BNCT is a relatively new treatment and cost varies significantly between centres. As a Chinese tertiary non-profit hospital, Xiamen Humanity Hospital offers BNCT and other cancer treatments at significantly lower cost than equivalent BNCT pathways in Japan (the other country actively offering accelerator-based BNCT at clinical scale) or any potential future BNCT centres in the United States or Europe. For non-BNCT cancer treatments, the hospital is broadly priced in line with Chinese tertiary private and non-profit hospitals, materially lower than equivalent care in Singapore, the US, UK or other high-cost healthcare markets. CancerFax shares the hospital's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with alternative BNCT options including Japanese centres, alternative Chinese oncology pathways, and international cancer treatment alternatives before any decision is made. We always recommend asking for a 'complication contingency' estimate alongside the base treatment cost, particularly for advanced refractory cancer cases where post-treatment supportive care may be substantial.